Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Lilly Is Helping To Address The UK’s ‘Postcode Lottery’ For Cancer Drugs

Executive Summary

Some innovative cancer drugs are not reaching eligible patients in the UK, despite securing positive reimbursement opinions from NICE. Eli Lilly explains how industry can be “part of the solution” through partnership initiatives.

You may also be interested in...



ABPI Presents Pre-Election Vision For Boosting UK Clinical Trials, Innovation & Manufacturing

The ABPI’s “manifesto for investment, health and growth” says that the new government to be elected later this year must ensure that investment in new medicines and research accelerates future innovation and attracts more R&D to the UK.

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

New EU guidance outlines the process through which scientific committees, national competent authorities and other relevant decision-makers can request real-world evidence studies for regulatory purposes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel